Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab. Objectives: ...
The introduction of lebrikizumab, a novel monoclonal antibody targeting interleukin-13 for severe atopic dermatitis (AD), was associated with cost savings of approximately €3.3 million over 3 years ...
Sight Sciences' analysis shows TearCare can save health plans $36.87 PMPY over traditional dry eye treatments in the U.S. Results from a Budget Impact Analysis indicate that a 20% increase in market ...
Second-generation anaplastic lymphoma kinase (ALK) inhibitors, including ceritinib, brigatinib, and alectinib, have improved survival in ALK-rearranged non-small-cell lung cancer (NSCLC) but are not ...
Pertuzumab/Docetaxel/Carboplatin/Trastuzumab Regimen in Human Epidermal Growth Factor Receptor 2–Positive Early, Locally Advanced, and Oligometastatic Breast Cancer ...
Humacyte, Inc. announced the publication of a Budget Impact Model for its bioengineered human tissue, Symvess, in the Journal of Medical Economics, indicating its cost-effectiveness for hospitals and ...
A phase II study of perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01): Report of interim analysis. This is an ASCO Meeting Abstract from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results